Cerebroprotective action of telmisartan by inhibition of macrophages/microglia expressing HMGB1 via a peroxisome proliferator-activated receptor γ-dependent mechanism

Neuroscience Letters

Volumn 464, Issue 3, 2009, Pages 151-155

  Haraguchi, Tamami ^a   Takasaki, Kotaro ^a   Naito, Tetsuya ^a   Hayakawa, Kazuhide ^a   Katsurabayashi, Shutaro ^a   Mishima, Kenichi ^a   Iwasaki, Katsunori ^a   Fujiwara, Michihiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Cerebral ischemia; High mobility group box1; Macrophage microglia; PPAR ; Telmisartan

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN PROTECTION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME BLOOD LEVEL; MACROPHAGE; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZIMIDAZOLES; BENZOATES; CEREBRAL CORTEX; HMGB1 PROTEIN; ISCHEMIC ATTACK, TRANSIENT; MACROPHAGES; MALE; MICE; MICROGLIA; NEUROPROTECTIVE AGENTS; PPAR GAMMA; REPERFUSION INJURY;

EID: 70149105016     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.08.043     Document Type: Article

References (28)

1. Abdelrahaman M., Sivarajah A., and Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc. Res. 65 (2005) 772-781
2. Abraham E., Arcaroli J., Carmody A., Wang H., and Tracey K.J. HMG-1 as a mediator of acute lung inflammation. J. Immunol. 16 (2000) 2950-2954
3. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravence M., Qi N., Wang J., Avery M.A., and Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 (2004) 993-1002
4. Chinetti G., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 49 (2000) 497-505
5. Clark R.B., Bishop-Bailey D., Estrada-Hernandez T., Hla T., Puddington L., and Padula S.J. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J. Immunol. 164 (2000) 1364-1371
6. Goebel M., Clemenz M., Staels B., Unger T., Kintscher U., and Gust R. Characterization of new PPARγ agonists: Analysis of telmisartan's structural components. Chem. Med. Chem. 4 (2009) 445-446
7. 1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J. Pharmacol. Exp. Ther. 298 (2001) 62-70
8. Greene M.E., Blumberg B., McBride O.W., Yi H.F., Kronquist K., Hsieh L., Greene G., and Nimer S.D. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Exp. 4 (1995) 281-299
9. Gurley C., Nichols J., Liu S., Phulwani N.K., Esen N., and Kielian T. Microglia and astrocyte activation by toll-like receptor ligands: modulation by PPAR-gamma agonists. PPAR Res. 2008 (2008) 453120
10. Hayakawa K., Mishima K., Irie K., Hazekawa M., Mishima S., Fujioka M., Orito K., Egashira N., Katsurabayashi S., Takasaki K., Iwasaki K., and Fujiwara M. Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism. Neuropharmacology 55 (2008) 1280-1286
11. Hayakawa M., Mishima K., Nozako M., Hazekawa M., Mishima S., Fujioka M., Orito K., Egashira N., Iwasaki K., and Fujiwara M. Delayed treatment with minocycline improves neurological impairment via activated microglia expressing high-mobility group box1 inhibiting mechanism. Stroke 39 (2008) 951-958
12. Huttunen H.J., and Rauvala H. Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J. Intern. Med. 255 (2004) 351-366
13. Iwai M., Inaba S., Tomono Y., Kanno H., Iwanami J., Mogi M., and Horiuchi M. Attenuation of focal brain ischemia by telmisartan, an angiotensin II type1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice. Hypertens. Res. 31 (2008) 161-168
14. Iwai M., Tomono Y., Kanno H., Iwanami J., and Horiuchi M. Attenuation of focal brain ischemia by telmisartan, an angiotensin II type1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice. Hypertens. Res. 31 (2008) 161-168
15. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
16. Kim J.B., Sig Choi J., Yu Y.M., Nam K., Piao C.S., Kim S.W., Lee M.H., Han P.L., Park J.S., and Lee J.K. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J. Neurosci. 26 (2006) 6413-6421
17. Marchall T.G., Lee R.E., and Marchall F.E. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR, CCR2b. Theor. Biol. Med. Model. 3 (2006) 1
18. Marx N., Sukhova G., Murphy C., Libby P., and Plutzky J. Macrophages in human atheroma contain PPAR gamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPAR gamma activation in mononuclear phagocytes in vitro. Am. J. Pathol. 153 (1998) 17-23
19. Miyamoto N., Zhang N., Tanaka R., Liu M., Hattori N., and Urabe T. Neuroprotective role of angiotensin II type2 receptor after transient focal ischemia in mice brain. Neurosci. Res. 61 (2008) 249-256
20. Ombrellino M., Wang H., Ajemian M.S., Talhouk A., Scher L.A., Friedman S.G., and Tracey K.J. Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock. Lancet 354 (1999) 1446-1447
21. Randy L.H., and Guoying B. Agonism of peroxisome proliferator receptor-gamma may have therapeutic potential for neuroinflammation and Parkinson's disease. Curr. Neuropharmacol. 5 (2007) 35-46
22. Ricote M., Huang J.T., Welch J.S., and Glass C.K. The peroxisome proliferator-activated receptor (PPARgamma) as a regulator of monocyte/macrophage function. J. Leukoc. Biol. 66 (1999) 733-739
23. Riuzzi F., Sorci G., and Donato R. The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J. Biol. Chem. 281 (2006) 8242-8253
24. Storer P.D., Xu J., Chavis J., and Drew P.D. Peroxisome proliferator-activated receptor gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J. Neuroimmunol. 161 (2005) 113-122
25. Takaya T., Kawashima S., Shinohara M., Yamashita T., Toh R., Sasaki N., Inoue N., Hirata K., and Yokoyama M. AngiotensinII type1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in applipoprotein E-deficient mice. Atherosclerosis 186 (2006) 402-410
26. van Zoelen M.A., Yang H., Florquin S., Meijers J.C., Akira S., Arnold B., Nawroth P.P., Bierhaus A., Tracey K.J., and Poll T. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box1-induced inflammation in vivo. Shock 31 (2009) 280-284
27. Victor N.A., Wanderi E.W., Gamboa J., Zhao X., Aronowski J., Deininger K., Lust W.D., Landreth G.E., and Sundararajan S. Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur. J. Neurosci. 24 (2006) 1653-1663
28. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., Frazier A., Yang H., Ivanova S., Borovikova L., Manogue K.R., Faist E., Abraham E., Andersson J., Andersson U., Molina P.E., Abumrad N.N., Sama A., and Tracey K.J. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285 (1999) 248-251